Predictive markers in advanced renal cell carcinoma

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 459-464

  Michaelson, M Dror ^a   Stadler, Walter M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; ASTHENIA; CANCER RISK; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG EFFICACY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; KIDNEY NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84883183676     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.05.001     Document Type: Article

References (32)

1. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16:1745-55.
2. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res. 2004;10:6310S-4S
3. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
4. Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res;17:5443-50.
5. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
6. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763-73.
7. A. Bamias, G. Lainakis, and E. Manios Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib J Chemother 21 2009 347 350
8. M.H. Langenberg, C.M. van Herpen, and J. De Bono Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors J Clin Oncol 27 2009 6152 6159
9. Schuster C, Eikesdal HP, Puntervoll H, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One. 2012;7:e38364.
10. Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010;29:95.
11. M. Scartozzi, E. Galizia, and S. Chiorrini Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 2009 227 230
12. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-9.
13. M. Michaelson, D. Cohen, and S. Li Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Clin Oncol 29 suppl 7 2011 320a
14. I. Puzanov, M. Michaelson, D. Cohen, S. Li, P. Burnett, and J. Desai Evaluation of hand-foot syndrome as a potential biomarker of sunitinib efficacy in patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor J Clin Oncol 29 2011 e21113a
15. F. Donskov, M.D.P. Michaelson, and M.P. Davis Comparative assessment of sunitinib-associated adverse events as potential biomarkers of efficacy in metastatic renal cell carcinoma ESMO Proc 2012 abstract 785O
16. C.M. Hartford, A.A. Desai, and L. Janisch A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies Clin Cancer Res 15 2009 1428 1434
17. Lee CK, Marschner IC, Simes RJ, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res. 2012;18:3188-96.
18. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402-7.
19. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13:827-37.
20. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28:475-80.
21. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-8.
22. C.G. Moertel, and J.A. Hanley The effect of measuring error on the results of therapeutic trials in advanced cancer Cancer 38 1976 388 394
23. Oxnard GR, Zhao B, Sima CS, et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011;29:3114-9.
24. Sharma MR, Karrison TG, Jin Y, et al. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012;18:2309-15.
25. S. Halabi, B. Rini, W.M. Stadler, and E.J. Small Use of progression-free survival to predict overall survival in patients with metastatic renal cell carcinoma J Clin Oncol 28 2010 4525a
26. O.M. Hahn, C. Yang, and M. Medved Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma J Clin Oncol 26 2008 4572 4578
27. K.T. Flaherty, M.A. Rosen, and D.F. Heitjan Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma Cancer Biol Ther 7 2008 496 501
28. Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res. 2010;16:1216-1225.
29. Williams R, Hudson JM, Lloyd BA, et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology. 2011;260:581-590.
30. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010;194:1470-8.
31. Kayani I, Avril N, Bomanji J, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011;17:6021-8.
32. J.L. Chen, D.E. Applebaum, M. Kocherginsky, W.K. Rathmell, D. McDermott, and W.M. Stadler FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer J Clin Oncol 29 2011 e15047a